Enanta Pharmaceuticals (ENTA) to Release Quarterly Earnings on Monday

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) will release its earnings data after the market closes on Monday, August 8th. Analysts expect Enanta Pharmaceuticals to post earnings of ($1.32) per share for the quarter. Parties that wish to listen to the company’s conference call can do so using this link.

Enanta Pharmaceuticals (NASDAQ:ENTAGet Rating) last released its earnings results on Monday, May 9th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing the consensus estimate of ($1.43) by ($0.20). The company had revenue of $18.72 million during the quarter, compared to the consensus estimate of $20.40 million. Enanta Pharmaceuticals had a negative return on equity of 28.80% and a negative net margin of 122.68%. During the same period in the previous year, the firm posted ($1.09) EPS. On average, analysts expect Enanta Pharmaceuticals to post $-6 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Enanta Pharmaceuticals Stock Performance

ENTA opened at $70.96 on Friday. The company has a 50-day moving average of $48.06 and a 200-day moving average of $57.86. The company has a market capitalization of $1.47 billion, a P/E ratio of -12.86 and a beta of 0.58. Enanta Pharmaceuticals has a 1-year low of $37.59 and a 1-year high of $102.00.

Institutional Investors Weigh In On Enanta Pharmaceuticals

Large investors have recently made changes to their positions in the company. State Street Corp raised its holdings in shares of Enanta Pharmaceuticals by 16.1% during the first quarter. State Street Corp now owns 1,308,586 shares of the biotechnology company’s stock valued at $93,145,000 after acquiring an additional 181,517 shares during the period. Invesco Ltd. grew its position in Enanta Pharmaceuticals by 18.0% during the first quarter. Invesco Ltd. now owns 342,007 shares of the biotechnology company’s stock valued at $24,343,000 after purchasing an additional 52,163 shares in the last quarter. Charles Schwab Investment Management Inc. grew its position in Enanta Pharmaceuticals by 5.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 136,126 shares of the biotechnology company’s stock valued at $9,690,000 after purchasing an additional 6,863 shares in the last quarter. Walleye Capital LLC grew its position in Enanta Pharmaceuticals by 115.9% during the first quarter. Walleye Capital LLC now owns 63,046 shares of the biotechnology company’s stock valued at $4,488,000 after purchasing an additional 33,846 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its position in Enanta Pharmaceuticals by 6.2% during the first quarter. JPMorgan Chase & Co. now owns 39,557 shares of the biotechnology company’s stock valued at $2,815,000 after purchasing an additional 2,302 shares in the last quarter. Institutional investors and hedge funds own 98.87% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on ENTA. Royal Bank of Canada lifted their price target on shares of Enanta Pharmaceuticals from $64.00 to $67.00 and gave the company a “sector perform” rating in a report on Friday, July 1st. Roth Capital decreased their price target on shares of Enanta Pharmaceuticals from $101.00 to $70.00 in a report on Wednesday, May 11th. Robert W. Baird decreased their price target on shares of Enanta Pharmaceuticals from $130.00 to $90.00 and set an “outperform” rating for the company in a report on Thursday, May 19th. StockNews.com lowered shares of Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 22nd. Finally, JMP Securities reissued a “buy” rating and set a $103.00 target price on shares of Enanta Pharmaceuticals in a research note on Wednesday, June 22nd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $72.75.

About Enanta Pharmaceuticals

(Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

See Also

Earnings History for Enanta Pharmaceuticals (NASDAQ:ENTA)

Want More Great Investing Ideas?

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.